Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vigabatrin for Treatment of Methamphetamine Dependence: A Phase II Study

NCT00730522 is registered in ClinicalTrials.gov with Catalyst Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00730522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00730522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vigabatrin for Treatment of Methamphetamine Dependence: A Phase II Study
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2008
Completion date
November 30, 2009
Enrollment
55 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

methamphetamine dependence